$IVST Sales are up 55.8%. ($1,104,367 in Q2 co
Post# of 10141
(Total Views: 112)
Posted On: 07/23/2018 1:38:58 PM
$IVST Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804 in Q1). June Sales were highest ever, at 16.8% higher than May, the previous record.
End Q2 current assets of $877,861 include cash on hand of $561,062.
Our capital structure includes an unchanged free-trading float of 11,796,710 common shares. There are no convertible debts, no warrants or options outstanding.
Our headcount is 44 employees, up from 26 at the start of the quarter.
Our stock price is up 725% as of this past Friday, since our January 2, 2018 close. Since Thursday of last week IVST saw more than double average trading volume, following the StemVax announcement.
We received notice that Winslow Asset Management registered as a shareholder, marking our first institutional shareholder position.
We closed several key contracts with organizations ranging from local governments, to the United States Navy, University Hospitals, Cleveland Indians, University of Louisiana, Iowa Department of Transportation, Houston Metro, Tarkette and a $650K exclusive contact from Byram Healthcare, a division of a Fortune 500 Company.
We’ve got a world-class team including two independent members of our Board of Directors, and our key corporate leadership is highlighted on our new corporate website.
There isn’t a person on our team that hasn’t contributed exceptionally this first half of 2018. We could not be happier with our progress. We are attracting larger acquisition prospects and are engaging in discussions with opportunities that I categorize as “transformational”. We’ve now broadly proven our business model, and our ability to execute, and while we must continue to focus on organic results we are now also in pursuit of scaling our success to levels that will establish Innovest as a significant Conglomerates Industry player. This includes larger acquisitions, new attractive industry verticals, uplisted security status, more institutional exposure, and continued improvement. I’m extremely enthusiastic about our prospects for Q3, and expect to provide many additional updates soon. Congratulations again, and thank you to all our supporters!
Sincerely,
Daniel G. Martin
https://globenewswire.com/news-release/2018/0...eport.html
$ACOL $MJTK $COHO $DRUS $ANDI $IMTV $RSHN $LRDR $RDGL $WMIH $CELZ
End Q2 current assets of $877,861 include cash on hand of $561,062.
Our capital structure includes an unchanged free-trading float of 11,796,710 common shares. There are no convertible debts, no warrants or options outstanding.
Our headcount is 44 employees, up from 26 at the start of the quarter.
Our stock price is up 725% as of this past Friday, since our January 2, 2018 close. Since Thursday of last week IVST saw more than double average trading volume, following the StemVax announcement.
We received notice that Winslow Asset Management registered as a shareholder, marking our first institutional shareholder position.
We closed several key contracts with organizations ranging from local governments, to the United States Navy, University Hospitals, Cleveland Indians, University of Louisiana, Iowa Department of Transportation, Houston Metro, Tarkette and a $650K exclusive contact from Byram Healthcare, a division of a Fortune 500 Company.
We’ve got a world-class team including two independent members of our Board of Directors, and our key corporate leadership is highlighted on our new corporate website.
There isn’t a person on our team that hasn’t contributed exceptionally this first half of 2018. We could not be happier with our progress. We are attracting larger acquisition prospects and are engaging in discussions with opportunities that I categorize as “transformational”. We’ve now broadly proven our business model, and our ability to execute, and while we must continue to focus on organic results we are now also in pursuit of scaling our success to levels that will establish Innovest as a significant Conglomerates Industry player. This includes larger acquisitions, new attractive industry verticals, uplisted security status, more institutional exposure, and continued improvement. I’m extremely enthusiastic about our prospects for Q3, and expect to provide many additional updates soon. Congratulations again, and thank you to all our supporters!
Sincerely,
Daniel G. Martin
https://globenewswire.com/news-release/2018/0...eport.html
$ACOL $MJTK $COHO $DRUS $ANDI $IMTV $RSHN $LRDR $RDGL $WMIH $CELZ
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼